9-hydroxyellipticine has been researched along with Cancer of Pancreas in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kusumoto, M; Maehara, N; Mizumoto, K; Niiyama, H; Ogawa, T; Sato, N; Tanaka, M | 1 |
| Kusumoto, M; Li, Z; Maehara, N; Mizumoto, K; Niiyama, H; Nishio, S; Ogawa, T; Sato, N; Tanaka, M | 1 |
2 other study(ies) available for 9-hydroxyellipticine and Cancer of Pancreas
| Article | Year |
|---|---|
9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Base Sequence; DNA Primers; Ellipticines; Enzyme Inhibitors; Genes, p53; Humans; Pancreatic Neoplasms; Substrate Specificity; Telomerase; Tumor Cells, Cultured | 1998 |
Diverse effects of 9-hydroxyellipticine on the chemosensitivity of human pancreatic cancer cells harboring p53 mutations.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Drug Interactions; Drug Monitoring; Ellipticines; Humans; Mutation; Pancreatic Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |